Dexcom (NSDQ:DXCM) shares ticked up after hours on second-quarter results that topped the consensus forecast.
The San Diego-based continuous glucose monitor developer posted profits of $62.9 million, or 63¢ per share, on sales of $595.1 million for the three months ended June 30, 2021, for a 35.9% bottom-line gain on sales growth of 31.7%.
Get the full story at our sister site, Drug Delivery Business News.